|

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

RECRUITINGN/ASponsored by Shirley Ryan AbilityLab
Actively Recruiting
PhaseN/A
SponsorShirley Ryan AbilityLab
Started2025-02-01
Est. completion2026-07
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations1 site

Summary

This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago
* Relapse free for at least 6 months
* Expanded Disability Status Scale (EDSS) ≤7
* Index finger abduction strength \<5 according to Medical Research Council Scale, or 9-Hole Peg Test score \>20 seconds in at least one hand
* Stable disease modifying therapies for at least 6 months
* Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion Criteria:

* Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function
* Mini-Mental State Examination (MMSE) score \<24
* Modified Ashworth Scale score \>3 on elbow joint
* Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg)
* History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea
* Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain
* Pregnancy as confirmed by urine test

Conditions3

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive

Locations1 site

Shirley Ryan AbilityLab
Chicago, Illinois, 60611
Rachel Kravitt, OTD, OTR/L(312)238-3947rkravitt@sralab.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.